Physician profile
Jonathan Shumway
NPI 1982108650
$7,012.94
in general payments reported to CMS, 2019-2025
44 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $630 · 2022: $1,355 · 2023: $1,919 · 2024: $1,749 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,027.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,454.64 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $693.32 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $555.07 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $497.83 | 2022-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $488.65 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $452.73 | 2021-2025 | Repatha, Otezla, Evenity |
| Axsome Therapeutics, INC. | $298.60 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $246.18 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.78 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Mylan Specialty L.P. | $232.31 | 2021-2024 | Yupelri |
| Pfizer INC. | $169.66 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $163.32 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $135.38 | 2022-2025 | Rexulti |
| Edwards Lifesciences Corporation | $125.01 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Xeris Pharmaceuticals, INC. | $117.38 | 2021-2025 | Gvoke Hypopen |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $112.77 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $87.80 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $84.47 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $69.96 | 2021-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $59.18 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Neurocrine Biosciences, INC. | $57.59 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $52.79 | 2021-2024 | Xarelto |
| Aimmune Therapeutics, INC. | $46.42 | 2024-2025 | Zenpep |
| Supernus Pharmaceuticals, INC. | $45.34 | 2021-2025 | Qelbree |
| Glaxosmithkline, LLC. | $43.45 | 2023-2025 | Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $39.64 | 2023-2024 | Gemtesa |
| Amarin Pharma, INC. | $39.38 | 2021-2022 | |
| Dexcom, INC. | $38.59 | 2021-2022 | |
| Shield Therapeutics INC | $36.26 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $36.20 | 2021 | |
| Lundbeck LLC | $33.12 | 2023-2025 | Vyepti |
| Arbor Pharmaceuticals, INC. | $30.98 | 2022 | |
| Seqirus USA INC | $30.21 | 2021-2022 | |
| Ardelyx, INC. | $28.92 | 2024-2025 | Ibsrela |
| Csl Behring | $24.81 | 2023 | Haegarda |
| Actelion Pharmaceuticals US, INC. | $21.31 | 2024 | Opsumit, Uptravi |
| Radius Health, INC. | $21.10 | 2025 | Tymlos |
| Boston Scientific Corporation | $19.62 | 2023 | Wavewriter Alpha Prime 16 |
| Mannkind Corporation | $18.29 | 2021 | |
| Organon LLC | $14.27 | 2023 | Nexplanon |
| Avion Pharmaceuticals | $13.71 | 2022 | |
| Ucb, INC. | $12.09 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.46 | 2021 | |
| Clarus Therapeutics INC. | $10.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Shumway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.